← 홈

ADC · VEGF

3개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3개
ADCBiologicstaleAbbViePhase 3

Mirvetuximab soravtansine plus Bevacizumab (Mirvetuximab soravtansine plus Bevacizumab)

Ovarian Cancer; Peritoneal Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 100%임상시험 6상태 RECRUITING
ADCBiologicstaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin + tislelizumab + bevacizumab)

Lung Cancer · Lung Cancer

#LungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleThe First Affiliated Hospital o…Phase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Tirumotecan Combined with Bevacizumab)

Platinum-resistant Recurrent Ovarian Cancer (PROC) · Platinum-resistant Recurrent Ovarian Can

#Platinum-resistantRecurrentOvari#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING